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A
 
BSTRACT
 
After completion of sequencing of the human genome,
you will no longer be able to discover a new gene and
may not be able to find a new molecule in the human
body. Instead, you may find many new molecule net-
works. It will be possible to select information obtained
from animal models just where orthologous genes are
functioning similarly. Mouse disease models will not
be used any longer where key orthologous genes are
working differently than in humans. Analysis of cell
type-selective transcripts from database searches is
now available to minimize the efforts required for drug
discovery. As such, it will soon be possible to use com-
putational modeling to analyze integrative biological
function and to test hypotheses without performing any
 
in vivo
 
 or 
 
in vitro
 
 experimentation. However, before
establishing a system simulating the human body,
which consists of a variety of organs, which further
consist of various types of cells, which then consist of
various types of proteins, which consist of 20 types
of amino acids, there are many steps that need to be
understood.
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Being able to completely read the human genome
sequence, we will know all about the role of genomic
DNA sequence variations among individuals, such as a
single nucleotide polymorphism, in the pathogenesis
of diseases and responses to drugs. An understanding of
genome will also accelerate an understanding of the
transcriptome and the proteome, the functional elements
in a cell. We will not miss any messages induced by a
new therapy, such as an unexpected adverse effect,
using such a comprehensive assay.
 
1
 
 As such, the
sequencing of the human genome is offering unprece-
dented ‘system biology’, aiming for the understanding of
the total function of a cell, an organ or, in the near
future, the human body. An understanding of the genome
may provide a framework for modeling the human body
in the near future, using computational methods. It may
be possible to use computational modeling to analyze
integrative biological function and test hypotheses.
 
2
 
There are several different types of approaches to
predict total cellular function as a consequence of the
interaction of all molecules present in a cell. However,
most of the approaches are simulating the final cellular
function based on descriptions available in the literature
and not on whole genomic information. This is because
most genomic techniques, such as proteomics, are still in
their infancy and are impractical, except for transcrip-
tome analysis using microarray technology.
 
3–5
 
 We have
recently published two papers, which were performed by
mainly analyzing our transcriptome database based on
a high-density oligonucleotide microarray (GeneChip;
Affymetrix, Santa Clara, CA, USA). One paper dealt with
interspecies comparisons between human and mouse
mast cell transcriptomes,
 
4
 
 whereas the other paper con-
sidered the pharmaceutical development of anti-allergic
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drugs.
 
5
 
 Herein, I introduce a few examples of the studies
dealing with genome-wide information, mainly by
expanding the discussion of the two previously published
papers.
 
4,5
 
I
 
NTERSPECIES
 
 
 
COMPARISONS
 
Animal disease models have been used as surrogates for
humans and have been informative. The use of mouse
models for diseases related to allergy and immunology
has increased markedly because of the rapidly develop-
ing technologies and immunological tools to block
specific pathways or to selectively knock out genes that
are important for processes that contribute to the patho-
genesis of the disease. By using these technologies, the
genes responsible for several types of severe combined
immunodeficiency and common variable immuno-
deficiency have been found. Controversy does exist,
however, as to the relevance of these models of allergic
diseases, such as in asthma.
 
6,7
 
 Clinical trials sometimes
fail because of the fact that the results obtained in
animal studies cannot be reproduced in humans. For
instance, anti-interleukin (IL)-5 (eosinophil-growth factor)
antibody completely blocked the airway hypersensitivity
related to eosinophil inflammation in experimental
animal models of asthma.
 
8
 
 However, the therapeutic
application of humanized anti-IL-5 antibody did not
improve the bronchial hypersensitivity of asthmatics,
despite a marked decrease in eosinophil number.
 
9
 
 One
of the reasons why allergic disease models sometimes
fail to reproduce human diseases is the complexity of
human allergic diseases. Total loss of gene function
usually induces severe symptoms, but not the mild
symptoms seen in multifactorial diseases such as allergic
diseases.
 
1
 
 We have not yet succeeded in producing even
the simplest mouse model to test the hygiene hypothesis
to determine whether low, but not high, levels of
endotoxin in an environment induce allergic diseases.
We have examined genome-wide gene expression in
cultured human and mouse mast cells (triggering IgE-
mediated allergic reactions) to find molecules similarly
regulated and expressed by the two mast cell types.
 
4
 
Rodent mast cells are common experimental tools, but
are somewhat different from their human counterparts in
their responses to certain cytokines
 
10
 
 and anti-allergic
drugs.
 
11
 
After stimulation via high-affinity IgE receptor (Fc
 
ε
 
RI),
the transcriptional levels of several CC chemokines were
markedly increased and I-309 (CCL1), macrophage
inflammatory protein (MIP)-1
 
α
 
 (CCL3) and MIP-1
 
β
 
(CCL4) were found among the 10 most-increased human
and mouse transcripts from approximately 12 000 genes
and expressed sequence tags.
 
4
 
 High expression of CC
chemokines by both types of activated mast cell was con-
firmed at the protein level using ELISA. These results sug-
gests that mast cells play a crucial role in the recruitment
of various CCR-expressing cells into the tissue in an
IgE-dependent manner and that Fc
 
ε
 
RI-mediated induc-
tion of several CC chemokines is highly conserved
between humans and mice.
 
4
 
Recently, many human and mouse orthologous genes
have become available at a genome-wide level in elec-
tronic format (http://www.ncbi.nlm.nih.gov/Homology/),
which facilitates interspecies comparisons.
 
12
 
 However,
it has not been proven whether these structure-based
orthologs are similarly regulated. Among these ortholo-
gous genes, we found that major basic protein mRNA
levels were abundantly expressed by human mast cells,
but not by mouse mast cells.
 
13
 
 As such, some mRNA
expression was regulated differentially in mouse and
human mast cells (Table 1; http://www.nch.go.jp/imal/
Mast/Blood_Dec1_2002sup.xls). Therefore, studies on
the function of molecules highly expressed only in mouse
cells have to be interpreted with care with regard to their
potential function in humans. Interspecies comparison
studies of the expression of the whole genome should be
useful for the interpretation of experimental data from
animal models of human pathogenesis.
To simulate the human body in a computational
model, many animal models still have to be used. In the
near future, it will be possible to select information
obtained from animal models just where orthologous
genes are functioning similarly. Mouse disease models
will not be used any longer where key orthologous genes
are working differently than in humans, as shown in
Fig. 1.
 
‘D
 
RUGGABLE
 
’ 
 
GENES
 
 
 
FOR
 
 
 
ALLERGIC
 
 
 
DISEASES
 
Three types of circulating blood granulocytes (eosi-
nophils, basophils and neutrophils) and tissue mast cells
play roles in protecting against microbial infection by
releasing cell type-specific mediators and proteases.
Eosinophils, basophils and mast cells evoke allergic
reactions, as well as damaging nematodes.
 
14
 
 In addition
to killing bacteria, neutrophils sometimes induce sys-
temic vasculitis or multiple organ damage under certain
conditions.
 
15,16
 
 Thus, targeting granulocyte type-selective
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functions is considered an important strategy for drug
discovery. Activation of these cells is generally character-
ized by an influx of extracellular calcium (Ca
 
2+
 
), which is
essential for the subsequent release of granule-derived
mediators, newly generated lipid mediators and
cytokines.
 
17
 
 The flux of other ions plays an important role
during granulocyte responses because these ions regu-
late cell membrane potential and, thus, influence Ca
 
2+
 
influx.
 
18
 
 Treatment of mast cells and basophils with
pertussis toxin inactivates G
 
i
 
-proteins and abolishes
degranulation, but not the influx of Ca
 
2+
 
, induced by
non-immunological ligands such as thrombin and
 
N
 
-formylpeptide.
 
19
 
 Thus, the granulocyte degranulation
pathway is sometimes Ca
 
2+
 
 independent and is G-protein
dependent. Indeed, the thrombin-activated receptors
and formylpeptide receptors are classified as G-protein-
coupled receptors (GPR), having a seven transmem-
brane region.
 
20
 
 As such, ion channels and GPR both
play essential roles in degranulation, as well as other
cellular functions important for granulocytes, and are
thought to be good targets for drug development.
 
21
 
Receptor genes and ion channel genes are found only in
5 and 1.3% of all genes present in the human genome,
respectively.
 
22
 
 However, receptors and ion channels are,
respectively, found in 45 and 5% of the molecular
targets of all known drugs.
 
21,23,24
 
 In addition to their
 
Fig. 1
 
Orthologous genes that are regulated similarly or
differently in human and mouse cells. The expression levels of
287 pairs of orthologous genes were compared. Each point
represents the average of two (human) or three (mouse)
independent experiments shown at http://www.nch.go.jp/imal/
Mast/Blood_Dec1_2002sup.xls. You may use mouse disease
models if your research is investigating transcripts similarly
regulated in human and mouse cells (a). However, if the tran-
scripts are highly expressed only by human cells (b), you have to
use human cells or other animal models. If you found that the
transcripts were highly expressed only by mouse cells, you
should be careful in continuing your research (c).
 
Table 1
 
Representative orthologous genes that are regulated
similarly or differently in human and mouse cells (http://
www.nch.go.jp/imal/Mast/Blood_Dec1_2002sup.xls)
Transcripts regulated similarly in human and mouse cells
Tryptase
Heat shock 90 kDa protein
CCL2, monocyte chemotactic peptide (MCP)-1
Cathepsin D
Granzyme B
Carboxypeptidase A
CCL1, I-309
Cyclophilin B
Galectin-3
CCL4, macrophage inflammatory protein (MIP)-1
 
β
 
Osteopontin
 
L
 
-Histidine decarboxylase
Heat shock 60 kDa protein 1 (chaperonin)
Peroxiredoxin 1
Macrophage capping protein G-actin
Transcripts highly expressed only by human cells
Eosinophil major basic protein
Clusterin
Monoamine oxidase A
Macrophage migration inhibitory factor
Prostaglandin D
 
2
 
 synthase
15-Hydroxyprostaglandin dehydrogenase
Matrix metalloproteinase 9, type IV collagenase
GM-CSF
Syndecan 3
Siglec 6
Transcripts highly expressed only by mouse cells
Chondroitin proteoglycan
GM-CSF receptor 
 
β
 
 chain
Advillin
Thrombin receptor
Neutrophil cytosolic factor 4
CD100, semaphorin
STAT5b
TGF-
 
β
 
Carbonic anhydrase II
Cathepsin B
 
MCP, monocyte chemotactic protein; MIP, macrophage inflam-
matory protein; GM-CSF, granulocyte–macrophage colony stimulating
factor; STAT, signal transducers and activators of transcription; TGF,
transforming growth factor.
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physiological importance, receptors, including GPR and
those for ion channels, are considered to be marketable
and targeting these molecules should be efficient for
pharmaceutical development. That is, we can concen-
trate on approximately 2000 genes as practical drug
targets and can forget about the 30 000 other genes
present in the human genome.
We used GeneChip (U133A; Affymetrix) to examine
the cell type-selective transcriptome expression of seven
types of leukocytes (basophils, eosinophils, neutrophils,
CD4
 
+
 
 cells, CD8
 
+
 
 cells, CD14
 
+
 
 cells and CD19
 
+
 
 cells),
platelets, mast cells and fibroblasts. Then, we focused on
the expression of granulocyte-selective genes for ion
channels, GPR and other receptors. We identified 51
granulocyte-selective genes for ion channels and
receptors by examining approximately 20 000 types of
transcripts derived from 16 000 genes (approximately
half the number of genes present in the human genome)
from the 10 different types of cells.
 
5
 
 Twenty-two mast
cell-, basophil- and/or eosinophil-selective transcripts
identified in this study could be potential therapeutic
targets for allergic diseases (Table 2)
 
5
 
 because these
granulocytes play a crucial role in allergic inflamma-
tion.
 
14
 
 It is estimated that approximately 50 genes are
selectively expressed by mast cells, eosinophils and
basophils among all the genes present in the human
genome.
The safety of any candidate drug must be evaluated by
comparing its efficacy on these granulocytes with its toxic-
ity to physiologically important organs. Among the 22
receptors and ion channels, three molecules were highly
expressed by multiple normal tissue cell types (Table 2),
indicating that the remaining 19 molecules may be
potential targets for anti-allergic drugs. Analysis of cell
 
Table 2
 
Mast cell-, basophil- and eosinophil-selective transcripts for ion channels and receptors
Transcript (accession No. at GenBank) Cell-type selectivity
Ion channels
Ca
 
2+
 
 channel type A1 D (BE550599) Basophils, eosinophils
Histamine H
 
4
 
 receptor (AF312230.1) Basophils
Prostaglandin E receptor type 3a2 (X83858.1) Basophils
C3a receptor (U62027.1) Basophils, eosinophils
Chemokine receptor CCR3 (NM_001837.1) Basophils, eosinophils
CRTH2 (NM_004778.1) Basophils, eosinophils
EMR-1 (NM_001974.1) Basophils, eosinophils
Adenosine A
 
3
 
 receptor (NM_000677.2) Eosinophils
P2Y
 
2
 
 purinergic receptor (NM_002564.1) Eosinophils
GPR105 purinergic receptor (NM_014879.1) Eosinophils
Other receptors
Fc
 
ε
 
RI
 
α
 
 (BC005912.1) Basophils
HTm4 (L35848.1) Basophils
IL-3 receptor 
 
α
 
 (NM_002183.1) Basophils
CD244 NK cell receptor
 
†
 
 (NM_016382.1) Basophils, eosinophils
Fibroblast growth factor receptor 2†(NM_022969.1) Basophils, eosinophils
IL-5 receptor 
 
α
 
 (M75914.1) Basophils, eosinophils
Siglec 8 (NM_014442.1) Eosinophils
CD117 c-KIT (NM_000222.1)
 
†
 
Mast cells
Siglec 6 (D86358.1) Mast cells
Fc
 
ε
 
RI
 
β
 
 (NM_000139.1) Mast cells, basophils
Low-density lipoprotein receptor
 
†
 
 (NM_000527.2) Mast cells, basophils
TRK receptor (NM_002529.2) Mast cell, basophils
 
Cell type-selective transcripts were chosen from approximately 20 000 transcripts (GeneChip U133A; Affymetrix) based on the following criteria:
(i) the average mRNA expression level of each gene (obtained from three independent experiments) in a certain cell type must be threefold or
greater than the maximal level in other cell types; (ii) the average mRNA expression level of each gene must be significantly (
 
P
 
 < 0.01) greater than
that in other cell types; (iii) the expression level provided with ‘absence’ call by GeneChip Software should be observed only once or not at all in
three independent experiments; (iv) for transcripts preferentially expressed for the two different cell types, the average normalized expression levels
in the two cell types should be within threefold of each other.
CRTH2, chemoattractant receptor, homologous molecule expressed on Th2 cells; EMR, epidermal growth factor-like module-containing mucin-
like receptor; TRK, tropomyosin-related kinase neurotrophin; GPR, G-protein-coupled receptor; IL, interleukin.
 
†
 
Transcripts highly expressed by more than five different normal organs (http://www.lsbm.org/index_e.html).
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type-selective transcripts from database searches is
expected to minimize the efforts required for drug dis-
covery. By using genomic information, we can now filter
2000 marketable genes out of 34 000 genes present in
the human genome. Using the comparative expression
database regarding each cell type, we will be able to
further filter approximately 50 druggable genes for
allergic inflammation with regard to safety in addition to
marketability (Fig. 2).
 
I
 
S
 
 
 
THAT
 
 
 
ALL
 
 
 
THERE
 
 
 
IS
 
, 
 
MY
 
 
 
FRIEND
 
?
 
When you were a little child, you felt the world or even
your town spreading vast or endless. Now, you have
found it so small and perhaps you can easily draw the
map. Such was the whole of mankind. We once believed
that the genome contained almost limitless information.
However, after completion of sequencing of the human
genome, we, the grown-up mankind, would not think so.
We are not trying to discover the 12th Toll-like receptor
any more, because we already know that there are no
more than 10 or 11 Toll-like receptors by searching the
genome structure. In the near future, you may not be
able to find a new molecule in the human body. Instead,
in the next decade, you will find many new molecule
networks present in a cell. Then, you will be able to use
computational modeling to analyze integrative biologi-
cal function and test your hypothesis without performing
any 
 
in vivo
 
 or 
 
in vitro
 
 experimentation. However, before
establishing a simulation of the human body, which
consists of a variety of organs, consisting of various types
of cells, consisting of various types of proteins, consisting
of 20 types of amino acids, there are many steps that
need to be understood (Fig. 3).
 
Fig. 2
 
Filtering of ‘druggable’ genes through genomic infor-
mation. Only 34 000 genes were found to be contained in the
human genome. Using marketable (= easy to obtain the spe-
cific antagonist or agonist) criteria, 2000 genes were filtered as
drug targets. Using a cell-type specific transcriptome database,
these genes were further subclacified to be anti-allergic drug
targets or drug targets for other diseases. The estimated number
of anti-allergic (mast cell-, basophil- and eosinophil-specific)
drug targets was approximately only 50.
 
Fig. 3
 
Stairway to simulation biology. Before establishing a
simulation of the human body (organome), which consists of
a variety of organs (cellome), which consist of various types of
cells (proteome or transcriptome), which consist of various types
of proteins (sequencing), which consist of 20 types of amino
acids, there are many steps to be understood.
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